Author

Renata D'Incà

BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS
BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS

Renata D'Incà  et al.

COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Renata D'Incà  et al.

COMPARATIVE ASSESSMENT OF INFLIXIMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARATIVE ASSESSMENT OF INFLIXIMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Renata D'Incà  et al.

MACROPHAGES ACTIVATION IN NEWLY DIAGNOSED ILEOCOLONIC CROHN’S DISEASE
MACROPHAGES ACTIVATION IN NEWLY DIAGNOSED ILEOCOLONIC CROHN’S DISEASE

Renata D'Incà  et al.

SHORT DISEASE DURATION AND SUPERFICIAL PENETRATION WITHIN THE ILEAL WALL ARE ASSOCIATED TO M1 MACROPHAGES INFILTRATION AND ACTIVATION IN ILEOCOLONIC CROHN´S DISEASE
SHORT DISEASE DURATION AND SUPERFICIAL PENETRATION WITHIN THE ILEAL WALL ARE ASSOCIATED TO M1 MACROPHAGES INFILTRATION AND ACTIVATION IN ILEOCOLONIC CROHN´S DISEASE

Renata D'Incà  et al.

SWITCHING FROM ADALIMUMAB ORIGINATOR TO ABP 501 BIOSIMILAR: A MULTICENTRIC NORTH ITALIAN STUDY
SWITCHING FROM ADALIMUMAB ORIGINATOR TO ABP 501 BIOSIMILAR: A MULTICENTRIC NORTH ITALIAN STUDY

Renata D'Incà  et al.

THE ANTI IL-23/IL-12 AGENT USTEKINUMAB IS AN EFFECTIVE AND SAFE INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE REFRACTORY OR INTOLERANT TO ANTI-TNF: A MULTICENTRE ITALIAN STUDY
THE ANTI IL-23/IL-12 AGENT USTEKINUMAB IS AN EFFECTIVE AND SAFE INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE REFRACTORY OR INTOLERANT TO ANTI-TNF: A MULTICENTRE ITALIAN STUDY

Renata D'Incà  et al.

REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY
REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY

Renata D'Incà  et al.

DISEASE COURSE OF CROHN’S DISEASE DURING THE FIRST TEN YEARS FOLLOWING DIAGNOSIS IN A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT – THE EPI-IBD COHORT
DISEASE COURSE OF CROHN’S DISEASE DURING THE FIRST TEN YEARS FOLLOWING DIAGNOSIS IN A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT – THE EPI-IBD COHORT

Renata D'Incà  et al.

DISEASE COURSE OF ULCERATIVE COLITIS DURING THE FIRST TEN YEARS FOLLOWING DIAGNOSIS IN A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT – THE EPI-IBD COHORT
DISEASE COURSE OF ULCERATIVE COLITIS DURING THE FIRST TEN YEARS FOLLOWING DIAGNOSIS IN A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT – THE EPI-IBD COHORT

Renata D'Incà  et al.

THE ROAD TO AND SEQUENCE OF BIOLOGICAL THERAPY IN A POPULATION-BASED, EUROPEAN INCEPTION COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE -AN EPI-IBD COHORT STUDY
THE ROAD TO AND SEQUENCE OF BIOLOGICAL THERAPY IN A POPULATION-BASED, EUROPEAN INCEPTION COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE -AN EPI-IBD COHORT STUDY

Renata D'Incà  et al.

Item 1 - 11 / 11
1